About
533
Publications
44,514
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
12,801
Citations
Introduction
Skills and Expertise
Publications
Publications (533)
Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in the Swiss Dermatology Network of Targeted Therapy registry between 2011 and 2023. Quality of life was assessed using the Dermatological Life Qu...
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic and environmental factors, is limited in prevalence, and has proven quite difficult to treat. The symptoms it inflicts on those affected are quite debilita...
Dupilumab is a monoclonal antibody that works by inhibiting the activity of interleukin-4 and interleukin-13, two cytokines that play an integral role in the T helper 2 (Th2) immune response. It is FDA approved for the treatment of atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. For AD trea...
Quality of life impairment in dermatology patients and severity of psoriasis are quantified by the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI), respectively. The aim of this study is to compare the correlation between PASI and DLQI in patients from different geographical areas and to identify predictors of...
This nationwide cohort study included 452 patients (873 treatment series) and reported drug survival data on HS patients treated with biologics such as adalimumab, infliximab, ustekinumab and secukinumab. The median drug survival time for adalimumab was approximately 8 months but with bio-naïve patients having a significantly longer drug survival t...
Background
Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis.
Objectives
To investigate the predictability of psoriatic arthritis in patients with psoriasis and to identify important predictors.
Metho...
Background
Some patients treated with biologic therapy for psoriasis experience adverse events causing treatment discontinuation.
Objectives
To identify predictors of adverse events resulting in discontinuation of biologics for psoriasis.
Methods
This cohort study involved data from the Danish nationwide registry DERMBIO. A classification algorit...
Background
Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics.
Objectives
To map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO) and psoriatic arthritis (PsA), as well as the changes over...
Rosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed...
Atopic dermatitis (AD) is a common, chronic inflammatory dermatologic condition that can cause discomfort and thus negatively influence the mental health of patients. Research directly exploring the relationship between AD, anxiety, and symptoms of panic in a large United States (US) adult population is limited. We studied the relationship between...
Phototherapy has gained popularity in the recent decades for the treatment of various immune-mediated dermatological conditions since it is more-cost effective and less toxic compared to systemic therapies. This systematic review aims to inform dermatology providers of the risks and benefits of phototherapy, especially in patients at risk for malig...
Introduction:
Psoriatic arthritis is estimated to develop in 2% of patients with psoriasis per year and can result in significant morbidity. Early diagnosis and treatment of psoriatic arthritis are imperative to prevent irreversible arthritic joint damage. Dermatologists play a key role in identifying patients who are at risk for or with early sig...
Real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. The objective was thus to examine real-world performance of biologics in the treatment of psoriasis using the composite endpoint of either discontinuation or off-label dose escalation. Using a prospective nationwide registry (DERMBIO, 2007-2019), w...
Background:
Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Chile and Brazil are lacking. Understanding the availability and limiting factors of access to treatments can help to improve patient care and decrease long-term healthcare costs.
Objective:
In association with the Globa...
Objective:
We sought to determine the risk of contracting coronavirus disease (COVID-19) in individuals with alopecia areata (AA) compared to individuals without AA.
Methods:
We queried the Symphony Health-derived data from the COVID-19 Research Database, and individuals with a diagnosis of AA from 2019 to 2020 were included in the AA cohort. Su...
Background
Children with atopic dermatitis (AD) may have disturbed sleep, affected self-esteem and decreased quality of life, likely interfering with performance in school.
Objectives
To examine the association between hospital-managed paediatric AD, school performance and cognitive function.
Methods
In this cross-sectional study we linked data f...
Importance
Identifying the optimal long-term biologic therapy for patients with psoriasis is often done through trial and error.
Objective
To identify the optimal biologic therapy for individual patients with psoriasis using predictive statistical and machine learning models.
Design, Setting, and Participants
This population-based cohort study us...
Phototherapy is a standard treatment for moderate-to-severe psoriasis. However, concern remains regarding the associated cutaneous carcinogenic risk. Our objective is to conduct a systematic review of skin cancer risk for psoriasis patients treated with phototherapy. To achieve our goal, we searched Cochrane, PubMed, and Embase databases. We aimed...
Objective:
Although biologics are highly effective in the treatment of psoriasis, some patients consistently fail monotherapy. For these patients, combination therapy is commonly employed. However, evidence-based recommendations for combination therapy in the treatment of psoriasis with interleukin-17 (IL-17) inhibitors are currently lacking. Ther...
Background:
Prolonged systemic antibiotic treatment is often a part of management of hidradenitis suppurativa (HS). While biologic therapies are now available, the patient's treatment journey leading to biologic therapy is unclear.
Objectives:
To examine treatment patterns and duration of systemic treatment use in HS patients preceding biologic...
Since the advent of biologic treatments for psoriasis in the early 2000s, this class of medicines has proven to be a safe and effective therapeutic option in the treatment of moderate-to-severe psoriasis. Numerous biologic treatment options have been developed in the past 20 years, allowing for tailored treatment regimens for psoriasis in special p...
Importance
Biologics are important in treating patients with hidradenitis suppurativa (HS). However, to our knowledge, data on their real-life performance and treatment patterns in HS are limited.
Objective
To examine the drug survival of biologic therapies for HS in a real-world setting.
Design, Setting, participants
This cohort study included a...
Amid the current COVID-19 pandemic, there is concern for increased risk of infection while on immunomodulatory therapy. Omalizumab, a monoclonal antibody, is an add-on therapy for the treatment of chronic idiopathic urticaria (CIU) when first line therapy alone fails to achieve appropriate response. Current understanding of the response to COVID-19...
IntroductionAtopic dermatitis (AD) can have a profound negative impact on the quality of life (QoL) of patients. We analyzed the long-term changes in AD symptoms, QoL, and patient assessment of treatment effect in adults with moderate-to-severe AD treated for 2 years with dupilumab.
MethodsLIBERTY AD OLE (NCT01949311) is a multicenter, open-label e...
Background
Risankizumab has demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis in randomized clinical trials.
Objectives
We evaluated safety data from risankizumab psoriasis phase 1–3 clinical trials.
Methods
Short-term safety (through week 16) was analyzed using integrated data from five phase 2 and 3 clinical...
Background:
Due to the public health risk associated with SARS-CoV-2 (COVID-19) infection, universal use of face masks has been recommended to protect against viral spread. Adverse facial reactions from the utilization of masks in the general public are poorly characterized in literature.
Objective:
We aimed to provide a systematic review of stu...
IntroductionAtopic dermatitis (AD) is a systemic inflammatory condition that may increase the risk of cardiovascular disease (CVD); however, ongoing debate exists surrounding its direct association. We aimed to elucidate whether AD contributes to a higher incidence of CVD and major adverse cardiovascular events (MACE) in adult patients with AD, ind...
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in patients who are eligible for phototherapy or systemic therapy. The drug increases cyclic...
In April 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines regarding the management of psoriasis with a focus on its extracutaneous manifestations-comorbidities, mental health, psychosocial wellness, and quality of life (QOL). These guidelines provide the most up-to-date evidenc...
Biologics have impacted the clinical management of moderate to severe psoriasis. This review article highlights new data findings from phase 3 clinical trials (N=8) published between May 2020 and February 2021. Data on the efficacy of US Food and Drug Administration-approved biologics for treating psoriasis affirms durable skin clearance in the pre...
Background:
Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Objective:
We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis.
Methods:
Guidelines f...
Purpose
The aim of this review is to compare and contrast evidence‐based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis.
Materials and methods
Clinical practice guidelines from the American Academy of Dermatology (AAD), National Psoriasis Foundation (NPF), British Association of Dermat...
In the context of the current coronavirus disease 2019 (COVID‐19) pandemic, there is no direct evidence to support any preferred biologic therapy for psoriasis. However, known safety profile of different classes of biologic therapies as well as individual risk factors for infections must be considered. Here, we report incidence rates of respiratory...
The emergence of data from clinical trials of biologics, the approval of new biologics, and our improved understanding of psoriasis pathogenesis have increased the therapeutic possibilities for the treatment of moderate-to-severe psoriasis. Biologics currently approved for the treatment of psoriasis include tumor necrosis factor inhibitors, interle...
Background: In the double-blind, placebo-controlled LIBERTY
AD PEDS phase 3 trial (NCT03345914) in children with severe
atopic dermatitis (AD), dupilumab significantly improved AD signs
and symptoms. We assess time to onset of improvement in
pruritus in children treated with dupilumab.
Methods: Children aged 6–11 years were randomized to
dupilumab...
While interleukin‐17 (IL‐17) inhibitors are effective for many patients with psoriasis, there is limited real‐world data characterizing patients who respond or do not respond to this biologic class.1 Identification of patient characteristics associated with response to this class of medication would present a significant advantage for both patients...
Purpose of Review
Deucravacitinib is an oral, selective TYK2 inhibitor that is currently in phase III of development for the treatment of psoriasis. This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib.
Recent Findings
Phase II results for deucravacitinib...
Free open access data sources are a valuable tool for dermatology researchers and may uncover crucial information about dermatological diseases and delivery of dermatological care. This short review discusses six open access data sources including: National Health and Nutrition Examination Survey (NHANES), National Health Interview Survey (NHIS), N...
Introduction:
A number of treatments for atopic dermatitis (AD) are available; however, long-term treatment patterns and healthcare consumption in patients with AD are poorly described.
Methods:
We conducted a registry-based longitudinal drug utilization study among Danish patients with AD that were referred to their first-ever visit at hospital...
To the Editor: Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease associated with arthritis of inflammatory etiology such as rheumatoid arthritis¹. To date, the association between AD and non‐inflammatory arthritides remains unknown. This study sought to determine whether AD is associated with increased risk of osteoarthritis (...
In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity...
IL-23 inhibitors are a newer class of biologics that specifically target the p19 subunit of IL-23, a cytokine believed to play an important role in the pathogenesis of psoriasis. Currently, three IL-23 inhibitors have been developed for psoriasis: guselkumab, tildrakizumab, and risankizumab. Guselkumab was US Food and Drug Administration (FDA) appr...
Risankizumab is a humanized IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23). It has demonstrated substantial clinical efficacy in the treatment of psoriasis. This chapter reviews the efficacy and safety of risankizumab for the treatment of psoriasis as evidenced by the clinical trials to date. Four phase III trials h...
Introduction: Psoriasis, an immune-mediated disease that manifests cutaneously with possible arthritic complications, affects millions of people in the United States and worldwide. Depression and suicidal ideation and behavior (SIB) are two prevalent comorbidities associated with psoriasis, due to the chronic nature of the disease, lack of a cure,...
The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgari...
Background: Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other biologics for psoriasis treatment in North American dermatological practices. Materials & methods: Characteristics of patients ascertained at registry enrollment are described via mea...
Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the United States, brodalumab carries a boxed warning about suicidal...
Brodalumab, a first-in-class interleukin-17 (IL-17) receptor blocker, carries a black box warning for suicidal ideation and behavior, yet it is also one of the most powerful biologic agents in our armamentarium. We wish to highlight three patients with moderate-to-severe psoriasis and comorbid depression who were successfully treated with brodaluma...
In November 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released their recommendations regarding management of psoriasis in pediatric patients. The guidelines include information on quantification of disease severity, identification of triggers, assessment of comorbidities, and therapeutics specific t...